Centre for Research on Drugs & Health Behaviour, London School of Hygiene & Tropical Medicine, London, UK.
HIV/AIDS, Sexually Transmitted Infections and Viral Hepatitis Programme, World Health Organization (WHO) Regional Office for Europe, Copenhagen, Denmark.
Epidemiol Infect. 2014 Feb;142(2):270-86. doi: 10.1017/S0950268813000940. Epub 2013 May 29.
Knowledge of hepatitis B and C prevalence, and numbers infected, are important for planning responses. Published HBsAg and anti-HCV prevalences for the 20 WHO European Region countries outside the EU/EFTA were extracted, to complement published data for the EU/EFTA. The general population prevalence of HBsAg (median 3·8%, mean 5·0%, seven countries) ranged from 1·3% (Ukraine) to 13% (Uzbekistan), and anti-HCV (median 2·3%, mean 3·8%, 10 countries) from 0·5% (Serbia, Tajikistan) to 13% (Uzbekistan). People who inject drugs had the highest prevalence of both infections (HBsAg: median 6·8%, mean 8·2%, 13 countries; anti-HCV: median 46%, mean 46%, 17 countries), and prevalence was also elevated in men who have sex with men and sex workers. Simple estimates indicated 13·3 million (1·8%) adults have HBsAg and 15·0 million (2·0%) HCV RNA in the WHO European Region; prevalences were higher outside the EU/EFTA countries. Efforts to prevent, diagnose, and treat these infections need to be maintained and improved. This article may not be reprinted or reused in any way in order to promote any commercial products or services.
了解乙型肝炎和丙型肝炎的流行率和感染人数对于规划应对措施非常重要。我们提取了欧盟/欧洲自由贸易区以外的世卫组织欧洲区域 20 个国家的乙型肝炎表面抗原（HBsAg）和抗丙型肝炎病毒（抗-HCV）的公布流行率，以补充欧盟/欧洲自由贸易区公布的数据。该区域七个国家的一般人群 HBsAg 流行率（中位数 3.8%，平均值 5.0%）范围为 1.3%（乌克兰）至 13%（乌兹别克斯坦），抗-HCV 流行率（中位数 2.3%，平均值 3.8%，十个国家）范围为 0.5%（塞尔维亚、塔吉克斯坦）至 13%（乌兹别克斯坦）。注射毒品者的这两种感染流行率最高（HBsAg：中位数 6.8%，平均值 8.2%，13 个国家；抗-HCV：中位数 46%，平均值 46%，17 个国家），男男性行为者和性工作者的流行率也很高。简单估计表明，世卫组织欧洲区域有 1330 万（1.8%）成年人有 HBsAg，1500 万（2.0%）有丙型肝炎病毒 RNA；欧盟/欧洲自由贸易区以外国家的流行率更高。需要维持和改善预防、诊断和治疗这些感染的努力。本文不得以任何方式重印或再利用，以推广任何商业产品或服务。
